ABII: Summary for Abraxis Bioscience Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 3:29am EST - Canadian Markets open in 6 hours and 1 minute.

To create a watchlist or portfolio of shares, Sign-in or Register

Abraxis BioScience, Inc. (ABII)

On Feb 9: 35.22 USD 0.00 (0.00%)

MORE ON ABII

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Abraxis Bioscience Inc. (NasdaqNM:ABII) Delayed quote data

Last Trade:	35.22 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	35.22
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	N/A

Day's Range:	N/A - N/A
52wk Range:	24.52 - 73.98
Volume:	0
Avg Vol (3m):	47,263.5
Market Cap:	1.41B
P/E (ttm):	N/A
EPS (ttm):	-6.63
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Free Annual Reports

Add ABII to Portfolio

Download Data

HEADLINES

•	Abraxis Bioscience to Spin Off Abraxis Health in 2010
	at Seeking Alpha (Sun, Jan 31)

•	Abraxis BioScience downgraded by Merriman
	Briefing.com (Thu, Jan 28)

•	ABRAXIS BIOSCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Thu, Jan 28)

•	Abraxis BioScience Confirms Plan to Spin-off Abraxis Health in 2010 and Announces Management Structure
	Business Wire (Thu, Jan 28)

•	$10,000 Will Be 2010 Consumable Cost For Human Genome Sequencing: Competition Developing Rapidly In This Sector According To First Analysis Equity Valuation Expert
	Wall Street Transcript (Wed, Jan 27)

•	Abraxis BioScience to Present at 28th Annual J.P. Morgan Healthcare Conference
	Business Wire (Fri, Jan 8)

•	ABRAXIS BIOSCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Tue, Dec 15)

•	[video] Craig Barrett's Healthy Endeavor
	at Forbes.com (Wed, Dec 9)

•	Abraxis Provides Overview of ABRAXANE® Study Results to Be Presented at the 32nd Annual San Antonio Breast Cancer Symposium
	Business Wire (Tue, Dec 8)

•	[$$] Small-Cap Weakness Shrinks a Nanotech ETF
	at RealMoney by TheStreet.com (Fri, Nov 27)

•	Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
	Wall Street Transcript (Fri, Nov 20)

More Headlines for ABII...

ANALYST

EPS Est (next year) (Dec-09) :	-3.10
EPS Est (in 2 years) (Dec-10) :	-2.13
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses.

Full Company Profile

Add to Portfolio

Email to a Friend

•